Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce the terms of a proposed non-brokered private placement for an aggregate principal amount of up to US$3.0 million of unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). The Company anticipates t
2026-02-02 12:10 PM EST | Sharp Therapeutics Corp.
PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success
Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a specialty pharmaceutical company, today announced a new strategic initiative to pursue Health Canada approval for generic semaglutide in Canada and, subject to regulatory approval, its commercialization. Semaglutide is the active ingredient in Ozempic® and Wegovy®. The initiative builds on PharmaTher's demonstrated regulatory and partnering e
Biotechnology, Pharmaceuticals
2026-02-02 9:27 AM EST | PharmaTher Holdings Ltd.
Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study
Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully co
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-02-02 7:00 AM EST | Theralase Technologies Inc.
Aires Enters Collaboration Agreement with Leading Wellness Expert Gary Brecka's Brand, The Ultimate Human
Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - American Aires Inc. (CSE: WIFI) (OTCQB: AAIRF) ("Aires" or the "Company"), a pioneer in advanced technology designed to transform electromagnetic field (EMF) environments to support health and well-being, entered a Collaboration Agreement (the "Agreement") with the Ultimate Human, LLC, the legal entity behind influencer Gary Brecka's wellness brand, The Ultimate
2026-02-02 6:00 AM EST | American Aires Inc.
OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Request for FDA Rolling Review submitted to FDA on January 30, 2026 Non-Clinical and CMC BLA modules submitted to FDA At FDA's request, Type D Meeting expected in March 2026 to review Comparative Oncology biomarker data from patients treated in OST-HER2 Phase 2b human clinical trial and OST-HER2 trial in spontaneous osteosarcoma in canines Final BLA clinical module expected to be submitted to FDA by end of March 2026 after Type D Mee
2026-02-02 6:00 AM EST | OS Therapies
TempraMed Enters Strategic Media Partnership with Dr. Phil's Envoy Media, Validating Product Portfolio and Accelerating Market Adoption Across the United States
Vancouver, British Columbia--(Newsfile Corp. - February 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce that it has entered into a strategic media partnership with Dr. Phil and Envoy Media, providing access to an audience of over 19 million monthly viewers which marks a significant step in acc
Technology, Biotechnology, Pharmaceuticals, Health
2026-02-02 3:00 AM EST | TempraMed Technologies Ltd.
Telo Genomics Announces Appointment of John Price as Chief Financial Officer
Toronto, Ontario--(Newsfile Corp. - January 29, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that John Price has been appointed as Chief Financial Officer, effective immediately. Mr. Price was appointed as Chief Financial Officer effective January 30, 2026. Mr. Price has
2026-01-29 8:00 AM EST | Telo Genomics Corp.
Nextleaf Reports Fiscal Year 2025 Financial Performance
Vancouver, British Columbia--(Newsfile Corp. - January 28, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a multi-patented life science company and Canadian cannabis processor, is pleased to report its financial results for the Fiscal Year (FY) 2025. For the twelve months ended September 30, 2025, the Company delivered a transformative performance, including a dramatic reduction in net loss, increased gross profit, a
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-01-28 4:30 PM EST | Nextleaf Solutions Ltd.
Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline
Montreal, Quebec--(Newsfile Corp. - January 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced the strengthening of its long-standing collaboration with Canadian Nuclear Laboratories ("CNL") as part of its strategic effort to accelerate and expand its proprietary radiopharmaceutical program. Defence has been collaborating with CNL on th
Biotechnology, Pharmaceuticals, Health
2026-01-28 8:40 AM EST | Defence Therapeutics Inc.
Izotropic Provides Corporate Update & Announces Non-Brokered Private Placement
British Columbia and Sacramento, California--(Newsfile Corp. - January 28, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, provides a corporate update and announces the intention to complete a small non-brokered private placement fina
2026-01-28 8:00 AM EST | Izotropic Corporation
Scryb Reports Fiscal 2025 Results; Strengthened Balance Sheet and Significant Cybeats Exposure
Toronto, Ontario--(Newsfile Corp. - January 28, 2026) - Scryb Inc. (CSE: SCYB) ("Scryb'' or the "Company") announces that it has filed its audited consolidated financial statements and Management's Discussion and Analysis for the fiscal year ended September 30, 2025 ("FY2025"). The filings are available on SEDAR+. Fiscal 2025 marked a transformative year for Scryb, highlighted by a materially strengthened balance sheet, significantly reduced operating costs, and a
Biotechnology, Healthcare and Hospitals, Health
2026-01-28 7:03 AM EST | Scryb Inc.
Neural's Portfolio Company Hanf.com Announces Sales Start of Ritual Herbs Nicotine and Tobacco Free Products
Toronto, Ontario--(Newsfile Corp. - January 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CB
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-27 10:00 AM EST | Neural Therapeutics Inc.
Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board
Encinitas, California--(Newsfile Corp. - January 27, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed leading retina specialist, Dr. Taiji Sakamoto, an expert in the treatment of retinal disease, to its Scientific Advisory Board. As an advisor, Dr. Sakamoto, currently the Chair of Ophthalmology at Kagoshima University, will contribute clinical and scientific insights to Kiora as it develops new therapeutics to address retinal diseases with high unmet needs. "As we deep
Biotechnology, Pharmaceuticals
2026-01-27 7:00 AM EST | Kiora Pharmaceuticals, Inc.
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ. Robert Bitterman, CEO and Chairman of th
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-26 8:15 AM EST | Phio Pharmaceuticals Corp.
Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules
Vancouver, British Columbia--(Newsfile Corp. - January 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed a production cycle for its MDMA and psilocybin capsules intended for supply into Australia under the Authorised Prescriber Scheme. The completed batch consists of 1,000 MDMA capsules in a 60 mg dosage form and 1,000 n
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-26 7:00 AM EST | Optimi Health Corp.
TempraMed Launches New Product "VIVI Med(TM)," Unlocking New Growth Opportunities in High-Value Biologics and Injectable Medications
Highlights Uses same fully patented, thermal-protection technology across product portfolio with four products in market that keep room temperature medications at optimal temperature Designed for medications beyond standard insulin pens, including vials, biologics, GLP-1 therapies, alternative epinephrine auto-injectors, and temperature- and light-sensitive glucose test strips Expanded portfolio to pursue larger
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-23 4:05 PM EST | TempraMed Technologies Ltd.
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has closed its previously announced private placement of units (the "Units") of the Company (the "Offering"), including the full exercise of the over-allotment option. Canac
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-01-23 9:16 AM EST | Cardiol Therapeutics Inc.
MustGrow Closes $2.0 Million Non-Brokered LIFE Offering
Saskatoon, Saskatchewan--(Newsfile Corp. - January 23, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce: the closing of its previously annoucned non-brokered private placement of 4,000,000 units of the Company (each, a "Unit") at a price of $0.50 per Unit for gross proceeds of $2,000,000 (the "LIFE Offering"). Each Unit consists of (i) one common share of the Company (a "Sh
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2026-01-23 7:00 AM EST | MustGrow Biologics Corp.
CBIH Evaluates a Potential Reg A Offering of Approximately $1,000,000 to Enable Commercial Launch, Statewide Educational Expansion, and Protection of Its Patent Portfolio
Houston, Texas--(Newsfile Corp. - January 21, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today that it is in the evaluation stage of a potential financing transaction under Regulation A (Reg A), in an estimated amount in the order of $1,000,000, subject to change, internal review, and applicable market and compliance conditions. CBIH clarifies that this communication reflects
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-01-21 7:00 AM EST | Cannabis Bioscience International Holdings
Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics
Montreal, Quebec--(Newsfile Corp. - January 21, 2026) - Defence Therapeutics Inc., (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company, today announced an evolution of its corporate positioning to reflect its focus as a precision intracellular drug-delivery company advancing its proprietary Accum® platform through both internal development programs and strategic partnerships. Designed to unlock the full potential of comple
Biotechnology, Pharmaceuticals, Health
2026-01-21 3:15 AM EST | Defence Therapeutics Inc.